Wiadomości

Eisai Report Five-Year Leqembi Data Showing Sustained Alzheimer's Benefit

NASDAQ

(RTTNews) - BioArctic AB's partner Eisai Co., Ltd. (4523.T) presented long-term data from the Phase 3 Clarity AD trial showing that continuous treatment with LEQEMBI (lecanemab-irmb) provided sustained benefits in patients with early Alzheimer's disease.

Przeczytaj pelny brief Veytics

Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.